Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 84 EV-to-OCF is 22.00 as of Jul. 18, 2026, which is 36% below its 10-year median of 34.50. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $273.99 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Sartorius AG ranks worse than 78.45% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sartorius AG's Enterprise Value is $22,735 Mil.
Sartorius AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $1,033 Mil. Therefore, Sartorius AG's EV-to-OCF for today is 22.00.
The historical rank and industry rank for Sartorius AG's EV-to-OCF or its related term are showing as below:
SARTF'
s EV-to-OCF Range Over the Past 10 Years
Min: 14.38 Med: 34.5 Max: 75.27
Current: 22.54
During the past 13 years, the highest EV-to-OCF of Sartorius AG was 75.27. The lowest was 14.38. And the median was 34.50.
SARTF's EV-to-OCF is ranked worse than 78.45% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 7.7
vs SARTF: 22.54
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sartorius AG's PE Ratio (TTM) for today is calculated as:
Sartorius AG's share price for today is $212.80.
Sartorius AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.797.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sartorius AG EV-to-OCF Related Terms
Sartorius AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sartorius AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sartorius AG's EV-to-OCF falls into.
Sartorius AG's current Enterprise Value is $22,735 Mil.
Sartorius AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,033 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EV-to-OCF of 22.00 as of Jul. 18, 2026. This is 36% below median its historical median of 34.50. Over the past decade, Sartorius AG's EV-to-OCF has ranged from 14.38 to 75.27. According to the industry distribution chart, Sartorius AG ranks #670 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 78.5%.
Is Sartorius AG's EV-to-OCF too high?
Sartorius AG's current EV-to-OCF of 22.00 is 36% below median its 10-year median of 34.50. Over the past 10 years, this metric has ranged from a low of 14.38 to a high of 75.27. The Medical Devices & Instruments industry median EV-to-OCF is 7.70. Sartorius AG's value of 22.00 is 185.7% above this industry median. Based on the distribution chart, Sartorius AG ranks #670 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #670 out of 854 companies for EV-to-OCF. This places Sartorius AG in the lower half of its industry. The industry median EV-to-OCF is 7.70. Sartorius AG's value of 22.00 is 185.7% above this benchmark. Historically, Sartorius AG's own EV-to-OCF has ranged from 14.38 to 75.27 over the past decade. While the company's 10-year median is 34.50 vs. the industry median of 7.70, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.70, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EV-to-OCF of 22.00 is 185.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EV-to-OCF is 22.00, which is 36% below median its own 10-year median of 34.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.99, compared to a current price of $212.80 — trading 22.3% below its estimated fair value. The current EV-to-OCF is 22.00, which is 36% below median its 10-year median of 34.50 and 185.7% above the Medical Devices & Instruments industry median of 7.70. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EV-to-OCF is 22.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.3% below its estimated GF Value™ of $273.99.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
EV-to-OCF: 22.00 (36% below median its 10-year median of 34.50)
GF Value™: $273.99 vs. price of $212.80 (22.3% below fair value)
Industry Position: 185.7% above the Medical Devices & Instruments median (#670 of 854)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
